ZHU, MOJUN M.D.
Medical Oncology · NPI 1376923581 · SCOTTSDALE, AZ
ZHU, MOJUN is a Medical Oncology in SCOTTSDALE, AZ, a member of 2 medical groups, who billed 38 distinct codes to Medicare Part B in 2024.
Groups: MAYO CLINIC (ROCHESTER, MN) · MAYO CLINIC ARIZONA (PHOENIX, AZ) — member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group
Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒
Provider overview · all codes · CY2024
All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.
Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Services | Beneficiary-episodes | Avg charge | Avg Medicare payment |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | premium | premium | premium | premium |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | premium | premium | premium | premium |
| J1453 | Injection, fosaprepitant, 1 mg | premium | premium | premium | premium |
| J9267 | Injection, paclitaxel, 1 mg | premium | premium | premium | premium |
| J9263 | Injection, oxaliplatin, 0.5 mg | premium | premium | premium | premium |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | premium | premium | premium | premium |
| J9041 | Injection, bortezomib, 0.1 mg | premium | premium | premium | premium |
| J2469 | Injection, palonosetron hcl, 25 mcg | premium | premium | premium | premium |
| J0461 | Injection, atropine sulfate, 0.01 mg | premium | premium | premium | premium |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | premium | premium | premium | premium |
| 96375 | Injection of additional new drug or substance into vein | premium | premium | premium | premium |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | premium | premium | premium | premium |
| J9190 | Injection, fluorouracil, 500 mg | premium | premium | premium | premium |
| J9045 | Injection, carboplatin, 50 mg | premium | premium | premium | premium |
| 99215 | Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more | premium | premium | premium | premium |
| J9206 | Injection, irinotecan, 20 mg | premium | premium | premium | premium |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | premium | premium | premium | premium |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | premium | premium | premium | premium |
| 96415 | Administration of chemotherapy into vein, each additional hour | premium | premium | premium | premium |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | premium | premium | premium | premium |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | premium | premium | premium | premium |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | premium | premium | premium | premium |
| J3490 | Unclassified drugs | premium | premium | premium | premium |
| J0640 | Injection, leucovorin calcium, per 50 mg | premium | premium | premium | premium |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | premium | premium | premium | premium |
| 96372 | Injection of drug or substance under skin or into muscle | premium | premium | premium | premium |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | premium | premium | premium | premium |
| J7030 | Infusion, normal saline solution , 1000 cc | premium | premium | premium | premium |
| 96361 | Infusion into a vein for hydration, each additional hour | premium | premium | premium | premium |
| 99205 | New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more | premium | premium | premium | premium |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | premium | premium | premium | premium |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | premium | premium | premium | premium |
| 96411 | Administration of additional new drug or substance into vein using push technique | premium | premium | premium | premium |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | premium | premium | premium | premium |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | premium | premium | premium | premium |
| 36591 | Collection of blood sample from implanted device | premium | premium | premium | premium |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.